Novaremed AG is focused on developing innovative non-opioid treatments for chronic pain, particularly targeting conditions such as painful diabetic peripheral neuropathy (PDPN) and chemotherapy-induced peripheral neuropathy (CIPN). Their lead product, NRD.E1, is an orally active small molecule that operates through a unique mechanism, distinct from traditional pain therapies, as it does not interact with opioid receptors or other common pain-related targets. NRD.E1 has received FDA Fast Track Designation and is currently undergoing a Phase 2b clinical trial to evaluate its safety and efficacy in treating PDPN. The drug has shown promising results in preclinical studies and earlier clinical trials, demonstrating a favorable tolerability profile and clinically relevant pain reduction.

In addition to NRD.E1, Novaremed's pipeline includes MP-101, a combination product aimed at preventing CIPN, which utilizes glutamate signaling modulation as its mechanism of action. MP-101 is currently in Phase 2 clinical trials and has shown potential in preclinical studies for addressing the pain and sensory abnormalities associated with CIPN. Another candidate, MP-103, is in preclinical development and also targets CIPN and other forms of peripheral neuropathy, demonstrating higher effectiveness in animal models compared to its components alone. Through these innovative approaches, Novaremed AG aims to meet the significant unmet medical needs for effective pain management without the risks associated with opioid treatments.

Switzerland

Novaremed AG is a clinical-stage Swiss biopharmaceutical company, HQ in Basel, Switzerland, with a subsidiary in Israel. Novaremed is developing an orally active, first-in-class, small molecule (NRD.E1), with a novel mechanism of action, to treat Diabetic Neuropathic Pain.

Novaremed AG

Company Details